Clinical trials: PD-L1
Small Cell Lung Carcinoma
Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)
This study is a rolling arm study of investigational agents as monotherapy or in combination with pembrolizumab in participants with anti-programmed cell death 1 (PD-1)/ programmed cell death ligand 1 (PD-L1) refractory ES-SCLC…
- Trial name
- NCT04938817
- Testing
- coformulation pembrolizumab/quavonlimab, lenvatinib, MK-4830
- Where
- 48 sites in United States, Australia and 10 more
- Volunteers
- 110 people
- Sponsor
- Merck Sharp & Dohme LLC
Carcinoma, Renal Cell
Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)
Substudy 03A is part of a larger research study that is testing experimental treatments for renal cell carcinoma (RCC). The larger study is the umbrella study (U03).
- Trial name
- NCT04626479
- Testing
- Pembrolizumab, Favezelimab/Pembrolizumab, Belzutifan
- Where
- 55 sites in United States, Australia and 12 more
- Volunteers
- 393 people
- Sponsor
- Merck Sharp & Dohme LLC
Biliary Tract Neoplasms
Programmed Death Ligand (PD-L1) Combined With Chemotherapy for Patients With BTC
This is a randomized, open-label, parallel-group multi-center study of Phase 3 study to assess the efficacy and safety of KN035 compared to standard of care (SOC) Gemcitabine-based chemotherapies in the treatment of participants…
- Trial name
- KN035-BTC (NCT03478488)
- Testing
- KN035 plus Gemcitabine & oxaliplatin, Gemcitabine & oxaliplatin
- Where
- China
- Volunteers
- 472 people
- Sponsor
- 3D Medicines (Sichuan) Co., Ltd.
Cervical Cancer
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
Researchers are looking for new ways to treat metastatic cervical cancer. Cervical cancer is cancer in the cervix, the lower part of the uterus (womb). Metastatic means the cancer has spread to other parts of the body.
- Trial name
- NCT07216703
- Testing
- Pembrolizumab, Sacituzumab Tirumotecan, Bevacizumab
- Where
- 191 sites in United States, Argentina and 27 more
- Volunteers
- 1,023 people
- Sponsor
- Merck Sharp & Dohme LLC
Non-Small Cell Lung Cancer
Biomarkers of Response to Pembrolizumab Combined With Chemotherapy in Non-Small Cell Lung Cancer (KEYNOTE-782, MK-3475-782)
Participants with Stage IV nonsquamous non-small cell lung cancer (NSCLC) without prior systemic treatment will be treated with standard of care pembrolizumab combined with platinum-doublet chemotherapy for 4 cycles, then…
- Trial name
- KEYNOTE-782 (NCT03664024)
- Testing
- Pembrolizumab, Pemetrexed, Carboplatin
- Where
- 15 sites in United States, Canada and 3 more
- Volunteers
- 118 people
- Sponsor
- Merck Sharp & Dohme LLC
Advanced Non-Small Cell Lung Cancer
A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small Cell Lung Cancer (EMPOWERVAX Lung 1)
This study is researching an investigational drug, called BNT116, in combination with cemiplimab. BNT116 and cemiplimab will each be called a "study drug", and together be called "study drugs".
- Trial name
- NCT05557591
- Testing
- BNT116, Cemiplimab
- Where
- 52 sites in United States, Georgia and 5 more
- Volunteers
- 51 people
- Sponsor
- Regeneron Pharmaceuticals
Non-small Cell Lung Cancer
QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors
This is a phase 1b/2 study to evaluate the safety and efficacy of metronomic combination therapy in subjects with NSCLC who have progressed on or after treatment with PD-1/PD-L1 inhibitors.
- Trial name
- NCT03169738
- Testing
- avelumab, Bevacizumab, Capecitabine
- Sponsor
- ImmunityBio, Inc.
Nasopharyngeal Carcinoma
A Phase III Study of YL201 in Recurrent or Metastatic Nasopharyngeal Carcinoma (TAISHAN-301)
This study was designed to compare the efficacy and safety of YL201 with Investigator's choice of chemotherapy in subjects with recurrent or metastatic nasopharyngeal carcinoma who have failed prior PD-(L)1 inhibitor and at least…
- Trial name
- NCT06629597
- Testing
- YL201, Docetaxel, Capecitabine
- Where
- China
- Volunteers
- 400 people
- Sponsor
- MediLink Therapeutics (Suzhou) Co., Ltd.
Advanced Non-squamous Non-small-cell Lung Cancer, Advanced Squamous Non-Small Cell Lung Carcinoma
Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer
This Phase 2, open-label, randomized study in non-small-cell lung cancer (NSCLC) is designed to evaluate the efficacy and safety of an intravenously delivered oncolytic vaccinia virus, Olvi-Vec, followed by platinum-doublet…
- Conditions
- Advanced Non-squamous Non-small-cell Lung Cancer, Advanced Squamous Non-Small Cell Lung Carcinoma, Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Squamous Non-Small Cell Lung Carcinoma
- Trial name
- VIRO-25 (NCT06463665)
- Testing
- Olvimulogene nanivacirepvec, Platinum chemotherapy: carboplatin or cisplatin, Non-platinum chemotherapy: paclitaxel or nab-paclitaxel for squamous cell NSCLC or pemetrexed for nonsquamous cell NSCLC
- Where
- 15 sites in United States
- Volunteers
- 142 people
- Sponsor
- Genelux Corporation
Advanced Solid Tumors
Study of Quavonlimab (MK-1308) in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-1308-001)
This study will assess the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of escalating doses of quavonlimab when used in combination with pembrolizumab in participants with advanced solid tumors.
- Trial name
- NCT03179436
- Testing
- Quavonlimab, Pembrolizumab, Pembrolizumab/Quavonlimab
- Where
- 53 sites in United States, Australia and 14 more
- Volunteers
- 415 people
- Sponsor
- Merck Sharp & Dohme LLC
Neoplasms
A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Cancer
This study is open to adults with advanced cancer (solid tumors) and people with advanced head and neck cancer. The study has 2 parts.
- Trial name
- NCT04958239
- Testing
- BI 765179, Ezabenlimab, Pembrolizumab
- Where
- 48 sites in United States, Australia and 13 more
- Volunteers
- 151 people
- Sponsor
- Boehringer Ingelheim
Muscle-invasive Bladder Cancer
A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Participants With High-risk Muscle-invasive Bladder Cancer (MIBC) Who Are ctDNA Positive Following Cystectomy
This is a global Phase III, randomized, placebo-controlled, double-blind study designed to evaluate the efficacy and safety of adjuvant treatment with atezolizumab compared with placebo in participants with MIBC who are…
- Trial name
- IMvigor011 (NCT04660344)
- Testing
- Atezolizumab, Signatera
- Where
- 141 sites in United States, Argentina and 21 more
- Volunteers
- 761 people
- Sponsor
- Hoffmann-La Roche
Solid Tumors
A Study of Selicrelumab (RO7009789) in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Solid Tumors
This is an open-label, multicenter study designed to assess the safety, pharmacokinetics, pharmacodynamics and activity of Selicrelumab administered in combination with Atezolizumab (ATZ) in participants with metastatic or…
- Trial name
- NCT02304393
- Testing
- Atezolizumab, Selicrelumab
- Where
- 11 sites in United States, Canada and 4 more
- Volunteers
- 140 people
- Sponsor
- Hoffmann-La Roche
Multiple Myeloma
Study of Pomalidomide and Low Dose Dexamethasone With or Without Pembrolizumab (MK-3475) in Refractory or Relapsed and Refractory Multiple Myeloma (rrMM) (MK-3475-183/KEYNOTE-183)
The purpose of this study is to compare the efficacy of pomalidomide and low dose dexamethasone with pembrolizumab (MK-3475) to that of pomalidomide and low dose dexamethasone without pembrolizumab in terms of Progression-Free…
- Trial name
- NCT02576977
- Testing
- Pembrolizumab, Pomalidomide, Dexamethasone
- Volunteers
- 251 people
- Sponsor
- Merck Sharp & Dohme LLC
Endometrial Cancer
Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy.
This is a multicenter, open-label, nonrandomized, Phase 2 umbrella study of retifanlimab in participants who have advanced or metastatic endometrial cancer that has progressed on or after platinum-based chemotherapy.
- Trial name
- POD1UM-204 (NCT04463771)
- Testing
- retifanlimab, epacadostat, pemigatinib
- Where
- 65 sites in United States, Belgium and 5 more
- Volunteers
- 206 people
- Sponsor
- Incyte Corporation
NSCLC
IO102 With Pembrolizumab, With or Without Chemotherapy, as First-line Treatment of Metastatic NSCLC
The purpose of this study is to determine if IO102 combined with pembrolizumab with or without chemotherapy is safe tolerable and effective in the treatment of Non-small Cell Lung Carcinoma (NSCLC).
- Trial name
- NCT03562871
- Testing
- IO102, pembrolizumab (Keytruda), Carboplatin (Carboplatin Kabi)
- Where
- 13 sites in Germany, Netherlands and 2 more
- Volunteers
- 109 people
- Sponsor
- IO Biotech
Advanced Non-small Cell Lung Cancer
KN046 Plus Lenvatinib in Subject With Advanced Non-Small Cell Lung Cancer in the Failure of Anti-PD-(L)1 Agent
This is a phase 2/3, multicenter, randomized, open, positive-controlled study of patients with advanced non-small cell lung cancer whose disease has progressed after prior anti-PD-(L)1 therapy.
- Trial name
- NCT05001724
- Testing
- KN046, Lenvatinib, Docetaxel
- Where
- China
- Volunteers
- 16 people
- Sponsor
- Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Solid Tumor, Adult
A Study to Assess AXN-2510 Treatment in Adult Patients With Advanced Solid Tumors
The goal of this clinical trial is to learn more about the side effects and best dose of AXN-2510 in adults with advanced solid tumors.
- Trial name
- NCT07159828
- Testing
- AXN-2510
- Where
- 7 sites in United States
- Volunteers
- 3 people
- Sponsor
- Axion Bio, Inc
Advanced Solid Tumor
Study of MK-1248 With and Without Pembrolizumab (MK-3475) for Participants With Advanced Solid Tumors (MK-1248-001)
In this study, participants with advanced solid tumors were assigned to receive escalating doses of either MK-1248 alone or MK-1248 in combination with pembrolizumab (MK-3475).
- Trial name
- NCT02553499
- Testing
- MK-1248, pembrolizumab
- Volunteers
- 37 people
- Sponsor
- Merck Sharp & Dohme LLC
Esophageal Cancer
Clinical Trial Evaluating TQB6411 Injection in Participant s With Esophageal Cancer
The Phase Ib stage of this study primarily aims to evaluate the tolerance and safety of TQB6411 Injection in participants with recurrent or metastatic Esophageal cancer who have previously failed treatment with PD-1/PD-L1…
- Trial name
- NCT07367516
- Testing
- TQB6411 Injection
- Where
- 30 sites in China
- Volunteers
- 105 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.